Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Last Updated: 03/03/16

Clinical Investigations Branch (CIB)

The Clinical Investigations Branch (CIB) is responsible for:

  • Scientific coordination and oversight of the NCI’s National Clinical Trials Network Program (NCTN)
  • Organization of comprehensive programs of preliminary and definitive clinical trials of precision medicine, such as Lung-MAP, ALCHEMIST, NCI-MATCH, and a pediatric version of NCI- MATCH
  • Organization of innovative treatment, single/multiple agent or combined modalities, for adult, adolescent, and pediatric populations
  • Facilitation and organization of clinical research including surgical and radiation therapy, as well as chemo-, biologic- and immuno-therapies in the treatment of cancer
  • Coordination with the extramural scientific community and other NCI programs, such as the Coordinating Center for Clinical Trials (CCCT), on identifying and prioritizing trials for disease-related research
  • Coordination with other NCI programs regarding collection, banking, and use of clinical biospecimens in conjunction with validated data from clinical trials
  • Collaboration with NCTN groups, consortia, cancer centers and other entities in the development/harmonization of research standards and methodologies
  • Collaboration with international clinical trials organizations
  • Oversight of pediatric drug development, from testing of novel agents through the Pediatric Preclinical Testing Consortium (PPTC) to clinical evaluations of novel agents by CIB-supported pediatric clinical trials organizations
  • Coordination and oversight of the adult and pediatric brain tumor consortia
  • Collaboration with the NCI Central Institutional Review Board (CIRB), which with one centralized review, enables investigators to enroll patients into NCTN trials significantly faster than when obtaining approval from a local IRB
  • Cooperation with the Cancer Trials Support Unit (CTSU), which simplifies admittance to NCTN trials for qualified clinical sites and supports the conduct of those clinical trials

About the Branch Chief

Meg Mooney, MD Meg Mooney, MD, MBA is the Chief of the Clinical Investigations Branch (CIB) of the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, at the NCI and oversees adult sarcoma cancer therapeutics. She was formerly the Interim Director of the Office of Evidence-Based Surgery at the American College of Surgeons in Chicago, Illinois. More…